Stocks and Investing
Stocks and Investing
Tue, July 20, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, July 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Initiated (SPRB) at Strong Buy and Held Target at $30 on, Jul 19th, 2021
Raghuram Selvaraju of HC Wainwright & Co., Initiated "Spruce Biosciences, Inc." (SPRB) at Strong Buy and Held Target at $30 on, Jul 19th, 2021.
Raghuram has made no other calls on SPRB in the last 4 months.
There is 1 other peer that has a rating on SPRB. Out of the 1 peers that are also analyzing SPRB, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $26 on, Tuesday, March 23rd, 2021
Contributing Sources